Rosacea Treatment Using Non-thermal (Cold) Atmospheric Plasma Device

Completed · Not applicable

Conditions studied: Rosacea, Papulopustular

In brief

10-13 patients will be enrolled to receive split face treatment: the control side will be treated with metronidazole cream, the intervention side will be treated with a cold atmospheric plasma device

Key facts

Study ID

NCT05592548

Run by

The Skin Center Dermatology Group

People needed

5

Starts

2024-01-02

Expected to finish

2024-06-30

Last updated by the study team

2024-12-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Papulopustular rosacea of the cheeks
• Ability to complete six weeks of twice-weekly treatments

You may not qualify if…

• substantial asymmetry of disease distribution
• previous failure of topical ivermectin treatment
• presence of any other facial dermatoses
• presence of any photosensitizing disorders
• systemic tetracycline, systemic or topical ivermectin treatment within 6 weeks of start date
• current or within prior 3 months treatment with systemic immune-suppressive medication

Where it is running

• The Skin Center Dermatology Group — New City, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.